Shapiro, Michael |
| Recruiting | 4 | 20000 | US | Atorvastatin 40 Mg Oral Tablet, Lipitor, Placebo oral tablet | Duke University, National Institute on Aging (NIA), National Heart, Lung, and Blood Institute (NHLBI), Wake Forest University Health Sciences | Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases | 12/26 | 12/26 | | |
NCT06292013: A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) |
|
|
| Recruiting | 3 | 12500 | Europe, Canada, Japan, US, RoW | Lepodisiran Sodium, LY3819469, Placebo | Eli Lilly and Company | Atherosclerotic Cardiovascular Disease (ASCVD), Elevated Lp(a) | 03/29 | 03/29 | | |
| Active, not recruiting | 3 | 9541 | Europe, Canada, Japan, US, RoW | Obicetrapib, Placebo | NewAmsterdam Pharma, Monash University | Atherosclerotic Cardiovascular Disease | 11/26 | 11/26 | | |
VICTORION-2P, NCT05030428: Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease |
|
|
| Active, not recruiting | 3 | 17004 | Europe, Canada, Japan, US, RoW | Inclisiran sodium 300 mg, Placebo | Novartis Pharmaceuticals | Atherosclerotic Cardiovascular Disease | 10/27 | 10/27 | | |
| Active, not recruiting | 3 | 14013 | Europe, Canada, US, RoW | Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL, KJX839, Placebo in 1.5ml | Novartis Pharmaceuticals | Primary Prevention of Atherosclerotic Cardiovascular Disease | 04/29 | 04/29 | | |
NCT05646381: A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis |
|
|
| Recruiting | 2 | 502 | Europe, Canada, US, RoW | Pelacarsen (TQJ230) 80mg, TQJ230, Matching placebo, Placebo | Novartis Pharmaceuticals | Aortic Stenosis | 01/29 | 01/29 | | |
| Recruiting | N/A | 3000 | US | Baseline, 30 Day Follow Up | University of Washington, Patient-Centered Outcomes Research Institute | Appendicitis | 10/24 | 10/25 | | |
| Recruiting | N/A | 2009 | US | Supraglottic airway device, LMA, King, igel, Standard airway management | Jason Sperry, United States Department of Defense | Trauma Injury, Airway Control | 03/25 | 03/26 | | |
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events |
|
|
| Recruiting | N/A | 7500 | US | The Cleerly CAD Staging System | Cleerly, Inc., CPC Clinical Research | Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome | 03/29 | 03/29 | | |
Cornier, Marc-Andre |
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events |
|
|
| Recruiting | N/A | 7500 | US | The Cleerly CAD Staging System | Cleerly, Inc., CPC Clinical Research | Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome | 03/29 | 03/29 | | |
Mushtaq, Ammara |
| Recruiting | N/A | 10000 | US | Blood work | Brooklyn Clinical Research | Cardiovascular Diseases, Obesity, PreDiabetes, Diabetes Type 2, Metabolic Syndrome | 04/29 | 04/29 | | |
| Recruiting | N/A | 10000 | US | | Brooklyn Clinical Research | Vaccination; Infection, HIV-1-infection, Infectious Disease | 01/29 | 01/29 | | |
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events |
|
|
| Recruiting | N/A | 7500 | US | The Cleerly CAD Staging System | Cleerly, Inc., CPC Clinical Research | Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome | 03/29 | 03/29 | | |
Megaly, Michael |
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events |
|
|
| Recruiting | N/A | 7500 | US | The Cleerly CAD Staging System | Cleerly, Inc., CPC Clinical Research | Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome | 03/29 | 03/29 | | |